Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by Eoganachton Apr 12, 2021 12:47pm
212 Views
Post# 32977915

RE:RE:Lumeda News

RE:RE:Lumeda NewsYes. They are using photofrin for the first phase 1 trial. That information has been on their website for a long time. If you contact Lumeda PR again ask them what PDC they will be using in the second phase 1 trial. I very much doubt they will tell you. When I contacted them months ago and asked them this, Paul Sanders wrote back and told me that the choice of PDC was up to Roswell Park not Lumeda. Here is the information available on the second phase 1 trial on Lumeda's website (TBD = to be decided):

Phase I Combination PDT-Immunotherapy (Information to be published once listed on the NIH clinical studies registry)
 
Title:   TBD
ClinicalTrials.gov Identifier:   TBD
Sponsor:   Roswell Park Comprehensive Cancer Center
Summary:  TBD
Primary Objective: TBD
Secondary Objectives:   TBD

stocksnbonds458 wrote: I contacted Lumeda PR regarding the PDT they are using in the human trials, they got back to me immediately. They are using Porfirmer Mediated Sodium PDT. https://clinicaltrials.gov/ct2/show/NCT03678350?term=NCT03678350&draw=2&rank=1


<< Previous
Bullboard Posts
Next >>